Elisabeth Perzborn

In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939—an oral, direct Factor Xa inhibitor

Elisabeth Perzborn, Andreas Wilmen, Jens Pohlmann et al. · Journal of Thrombosis and Haemostasis · 2005 · 584 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

NO-independent regulatory site on soluble guanylate cyclase

Johannes-Peter Stasch, Eva Maria Becker, Cristina Alonso‐Alija et al. · Nature · 2001 · 544 citations

Life Sciences, Biochemistry, Molecular Biology +9

Assessment of laboratory assays to measure rivaroxaban – an oral, direct factor Xa inhibitor

Jean-Luc Martinoli, Léna Leflem, Céline Guinet et al. · Thrombosis and Haemostasis · 2010 · 446 citations

Medicine, Pharmacology, Pharmacotherapy +17

Discovery of the Novel Antithrombotic Agent 5-Chloro-<i>N</i>-({(5<i>S</i>)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939):  An Oral, Direct Factor Xa Inhibitor

Susanne Roehrig, Alexander Straub, Jens Pohlmann et al. · Journal of Medicinal Chemistry · 2005 · 433 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +10

NO‐ and haem‐independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle

Johannes‐Peter Stasch, Péter Schmidt, Cristina Alonso‐Alija et al. · British Journal of Pharmacology · 2002 · 312 citations · Full text

Life Sciences, Biochemistry, Pharmacology +14